The role of B7 co-stimulatory signaling in in vivo tumor rejection remains incompletely characterized. In particular, the relative competence of B7-1 (CD80) and B7-2 (CD86) to provide effective co-stimulus is not well defined, and the identification of the T cell co-stimulatory receptor that mediates B7 co-stimulation in tumor rejection has not been addressed. These issues were studied by assessing rejection of B7-negative or B7-transfected tumor cells in CD28-expressing or CD28-deficient hosts. B7-negative EL4 tumor cells grew progressively in normal syngeneic C57BL/6 (B6) mice. In contrast EL4 cells transfected with either full length B7-1 or full length B7-2 were rejected, indicating that both B7-1 and B7-2 are competent to mediate rejection of EL4 tumor cells. Expression of truncated B7-1 or B7-2 products, with complete deletion of cytoplasmic domains, was as effective as expression of full length B7-1 or B7-2 in mediating rejection. In contrast to the rejection of B7-transfected EL4 cells observed in CD28-expressing syngeneic hosts, B7-1-and B7-2-positive EL4 cells as well as control EL4 cells grew progressively in CD28-deficient mice, demonstrating the requirement for host expression of CD28 in B7-mediated tumor rejection. These results indicate that interaction of host CD28 with co-stimulatory extracellular B7-1 or B7-2 ligands expressed on tumor cells can play a necessary role in mediating tumor rejection.
Introduction
The role of co-stimulatory signals in T cell activation has been identified in a number of in vitro and in vivo response systems (reviewed in [1] [2] [3] . A common observation in these models is that T cell stimulation by engagement of the TCR alone is not sufficient to induce full activation of a T cell response. Fully productive T cell activation requires, in addition to TCR engagement by specific antigen, a second or co-stimulatory signal provided by distinct receptor-ligand interactions (reviewed in 4). The most extensively characterized T cell costimulatory pathway is that mediated by the interaction of CD28 expressed on T cells with B7-1 (CD80) and/or B7-2 (CD86) expressed on a variety of cell types (5, 6) .
The role of co-stimulation in host response to tumors has received considerable recent attention. In a number of in vivo tumor transplantation systems, it has been observed that antigenic but B7-non-expressing syngeneic tumors grow progressively in host animals and fail to induce tumor-specific immunity, whereas B7 transfection augments the immunogenicity of these tumors and results in their rejection after in vivo challenge (7--9) . In these circumstances, immunization Received 29 September 1997, accepted 20 February 1998 with B7-transfected tumor cells results in protective immunity to subsequent challenge with the corresponding B7-nonexpressing tumors (8, 9) . Although the ability of B7 molecules to function in response to tumor challenge has been widely confirmed, some aspects of the role of co-stimulus in responses to tumor remain incompletely characterized. One of these is the relative competence of B7-1 and B7-2 to function as effective co-stimuli for tumor immunity. A number of studies have concluded that both B7-1 and B7-2 are competent to provide co-stimulus for anti-tumor responses (10) (11) (12) , whereas in some tumor models it has been concluded that B7-1 is superior to B7-2 in providing effective co-stimulatory signals (13) (14) (15) . B7-1 and B7-2 are members of the Ig supergene family which share only modest sequence homology, with particularly low homology in their cytoplasmic domains (16) . The present studies were therefore carried out to address the relative capacities of full length and cytoplasmic domain truncated B7-1 and B7-2 to mediate in vivo anti-tumor responses. A second question not previously addressed is the identification of the T cell co- 
B7 expression plasmids
Full length B7-1 cDNA and expression vector (LK444B7) (19) were kindly provided by Dr Ronald Germain (National Institutes of Health, Bethesda MD). B7-2 cDNA was obtained from Dr Gordon J. Freeman (Harvard Medical School, Boston, MA) (16) . B7-1 and B7-2 cDNA with desired restriction ends was generated by PCR cloning from full length cDNA. A translation stop codon was introduced at the end of the transmembrane domain of B7-1 and B7-2 to generate cytoplasmic domain deleted B7-1 and B7-2 (Table 1 and Fig. 1 ). The B7 cDNAs were cloned into the expression vector LK444B7 with the β-actin promoter and SV40 polyadenylation signal. The expression vector also carries Ampicillin and Geneticin (G418) resistance genes as selection markers. All PCR-cloned cDNA constructs were subsequently sequenced and confirmed to be sequence-identical to the reported cDNA sequence (data not shown).
Transfection
EL4 cells (10 7 ) were washed with OPTI-MEM medium (Life Technologies, Rockville, MD) and incubated with 10 mg linearized B7 cDNA constructs on ice for 10 min. The cells were then electroporated (960 mF, 300 V) on a Gene Pulsor (BioRad, Hercules, CA) and plated in 96-well culture plates at 10 4 -10 5 cells/well, with 500 mg/l G418 added after 24 h. The resistant clones were screened for the expression of B7 by flow cytometry after 10-14 days and positive cultures were sub-cloned by limiting dilution.
Flow cytometry analysis
A FACScan (Becton Dickinson, San Jose, CA) was used for flow cytometric analysis as previously described in detail (20) . Anti-FcR mAb 24G2 was first added to prevent non-specific binding of mAb to the cells. Cells were then incubated with FITC-labeled mAb, biotinylated mAb and streptavidinphycoerythrin conjugate sequentially. Between 1 and 3ϫ10 5 viable cells were analyzed.
Animal studies
The indicated numbers of EL4 cells were injected s.c. in 0.2 ml PBS into the shaved right back of mice. Tumor growth was monitored weekly and tumor size was measured as the average of two perpendicular diameters by a calliper. Mice were euthanized when tumors became ulcerated or mice otherwise appeared to be distressed or discomforted by tumor burden.
Results

B7-1 and B7-2 transfection of EL4 cells
The function of B7-1 and B7-2 in anti-tumor responses was analyzed using cells from the B6 T cell lymphoma EL4, which were either non-transfected or transfected with vector only (mock transfected), with cDNA encoding full length B7-1 or B7-2, or with truncated cDNA constructs encoding B7-1 or B7-2 lacking their cytoplasmic domains. Transfected EL4 cells were subcloned and analyzed by flow cytometry for expression of B7-1 or B7-2; and clones were selected which expressed comparable amounts of cell surface B7 (Fig. 2) . The in vitro growth rates of the clones employed were comparable (data not shown).
In vivo growth of B7-transfected EL4 cells
When B6 mice were challenged s.c. with 5ϫ10 4 non-transfected or mock transfected EL4 cells, tumors grew progressively in all recipient mice (Fig. 3) . In contrast, mice challenged with either full length B7-1-transfected or full length B7-2-transfected cells showed either no detectable tumor growth or transient growth followed by rejection and long-term tumorfree survival. Titration of tumor challenge dose over the range 2ϫ10 3 to 4ϫ10 6 cells did not reveal any difference in the growth patterns of B7-1-and B7-2-transfected EL4 cells (data not shown). Similar results were obtained in analysis of cells generated in two independent transfections with B7-1 or B7-2 (data not shown).
To determine the T cell-dependence of rejection of B7-transfected EL4 cells, athymic nude mice were challenged with tumor cells. B7-1-transfected, B7-2-transfected and control mock-transfected EL4 cells grew progressively in all athymic mice, and rates of tumor growth were similar in all groups (Fig. 4) . The failure to observe rejection of B7-transfected cells indicates that B7-mediated rejection is T cell dependent.
In vivo re-challenge of EL4 cells to mice immunized with B7-transfected EL4 cells One month after B6 mice had rejected B7-transfected EL4 cells, they were re-challenged s.c. with 2-10ϫ10 5 un-transfected EL4 cells. While naive B6 mice did not reject EL4 tumor cells (none of five mice rejecting tumor), eight of 10 of the mice that had previously rejected B7-1-EL4 cells rejected wild-type EL4 challenge and five of 10 of the mice that previously rejected B7-2-EL4 cells were able to reject wildtype EL4 challenge. In contrast, when pre-immunized mice were challenged with syngenic sarcoma 207 cells, tumors grew progressively. These results indicate that B7-transfected 
CD28 dependence of tumor rejection
The identity of the receptor(s) for B7-1 and B7-2 that function in rejection of B7-expressing tumors has not been previously demonstrated. The two known receptors for B7-1 and B7-2 are CD28 and CTLA-4. To directly assess the requirement for CD28 in rejection of transfected EL4 cells, responses to tumor challenge were analyzed in mice that had been rendered CD28 deficient by gene deletion through homologous recombination. B7-1-transfected and B7-2-transfected tumor cells were rejected in CD28-intact mice, while mock-transfected cells grew progressively (data not shown); in contrast, B7-1-, B7-2-and mock-transfected EL4 cells all grew progressively, and at similar rates in CD28-deficient mice (Fig. 5) . These results indicate that CD28 plays an essential role in rejection of B7-expressing tumors, suggesting that CD28 engagement by B7-1 and B7-2 expressed on tumor cells plays a critical role in the host response to EL4 tumor.
In vivo growth of EL4 cells transfected with truncated B7
The extracellular domains of B7-1 and B7-2 are capable of direct interaction with CD28 and CTLA-4 extracellular sequences (21, 22) . Little is known, however, about the requirement for B7 intracellular domains in mediating co-stimulatory function, e.g. through interaction with cytoskeleton or other intracellular components. To assess the role of B7-1 and B7-2 intracellular domains in tumor rejection, EL4 cells were transfected with cytoplasmic-deletion B7 constructs and these transfectants were analyzed in vivo. EL4 cells expressing truncated B7-1 or B7-2 molecules failed to grow in syngeneic B6 hosts, in contrast to the progressive tumor growth observed for mock transfectants (Fig. 6) . When higher tumor doses over the range 10 5 to 4ϫ10 6 cells were used to challenge naive B6 mice, truncated B7-1 EL4 cells were rejected by 15 of 15 mice and truncated B7-2 EL4 were rejected in 11 of 15 mice tested. The role of B7-1 and B7-2 expressed on EL4 tumor cells in mediating rejection therefore appears to be independent of the cytoplasmic domains of these co-stimulatory molecules.
Discussion
The EL4 thymoma has previously been studied as a model of antigenic but co-stimulus-deficient tumors which grow progressively in syngeneic hosts, but in which B7-1 transfection results in susceptibility to rejection. The present studies were designed to address several aspects of the role of B7 co-stimulatory molecules in in vivo tumor rejection responses. The first of these was the relative effectiveness of B7-1 and B7-2 as co-stimulatory ligands for tumor rejection. In a number of in vitro and in vivo T cell response systems other than tumor rejection, studies have generated discrepant answers to the question of whether B7-1 and B7-2 mediate fundamentally different T cell responses (23, 24) . In studies of B7 function in tumor rejection, there has similarly been no consensus. A number of reports have concluded that B7-1 and B7-2, when expressed on tumor cells, are both competent to mediate rejection of those tumors (10, 12, 25) ; others have reported that B7-1 is more efficient than B7-2 in providing co-stimulation for anti-tumor immunity (13) (14) (15) 26) . Although the basis for these differences is not clear, differences in the identity of the tumor used provide one potential explanation, based either on strength or quality of expressed 'tumor antigens' or upon differences in the pathways mediating rejection of different tumors. Differences in quantitative expression of B7 by transfected tumor cells can also contribute to the efficiency of B7 in mediating tumor rejection. In the studies reported here, equivalent efficiency of B7-1 and B7-2 transfection in mediating tumor rejection was observed over a wide range of challenge dosages, provided that comparable levels of B7-1 and B7-2 expression were selected. However, clones expressing a lower level of surface B7 were less efficiently rejected (data not shown). When mice immunized with B7-1-or B7-2-transfected cells were re-challenged with nontransfected EL4 cells, protection was observed in both groups. It is uncertain whether the differences observed between groups (tumor incidence: two of five for B7-1 versus five of 10 for B7-2 immunized mice) represent a significant difference between the capacities of B7-1 and B7-2 to induce tumor specific memory.
The identity of the co-stimulatory receptor molecules that function in B7-dependent tumor rejection has not previously been demonstrated. Two receptors for B7 molecules are known, CD28 and CTLA-4. In a number of in vivo and in vitro T cell responses, CD28 has been shown to function as a receptor for B7 co-stimulatory signals (5, 6) . In contrast, recent data have indicated that CTLA-4 may function as a predominantly down-regulatory receptor (27, 28) or as a positive co- stimulatory signal receptor (17) . In the present studies, it was found that either B7-1 or B7-2 expressed on EL4 cells can mediate rejection by CD28-expressing B6 hosts, but that neither B7-1 nor B7-2 mediates rejection in CD28-deficient hosts. Under these conditions, there is thus an absolute requirement for host CD28 to mediate B7-dependent tumor rejection. CD28-independent pathways, such as the interaction between CTLA-4 and B7 in CD28-deficient mice, are not sufficient to induce B7-dependent tumor rejection. A number of recent studies have shown that host NK cells, as well as T cells, are involved in killing of B7-1-and B7-2-expressing tumor cells both in vitro and in vivo (29) (30) (31) . Our study established a requirement for host T cells in in vivo EL4 rejection but did not rule out possible involvement of NK cells as well in the anti-EL4 response. Although more complex mechanisms might mediate this CD28 dependence, the most straightforward interpretation of these results is that CD28 expressed by host T cells functions as a receptor for costimulatory B7 ligands expressed by EL4 tumor cells and that the consequent co-stimulatory signaling plays an essential role in the T cell-dependent rejection response. Although tumor cell expression of B7-1 or B7-2 plays an essential role in tumor rejection under the experimental conditions studied, the overall requirement for co-stimulatory signaling in the rejection response may be complex. It is possible, for example, that co-stimulatory signaling of T cells by B7 expressed on host antigen-presenting cells (APC) also plays a role in anti-tumor responses, through pathways that may involve processing and presentation of tumor-specific antigens by host APC. Initial experiments have shown that B7-1- and B7-2-transfected EL4 cells are rejected by B7-1-deficient B6 mice as efficiently as by B7-intact mice (data not shown), indicating that host B7-1 expression is not required for rejection. To more definitively assess the role of host B7 in tumor rejection, it will be of interest to assess the ability of mice deficient in both B7-1 and B7-2 to reject B7-transfected tumor cells. The rejection of EL4 cells expressing truncated B7-1 and B7-2 molecules revealed that the cytoplasmic portions of these molecules are not essential for providing co-stimulus leading to tumor rejection. These results are informative in that they suggest that effective delivery of co-stimulatory signals, e.g. by CD28 engagement, can be mediated by binding of extracellular B7 ligands in the absence of additional signals contributed by cytoskeletal or other intra-cytoplasmic molecular associations in tumor cells. These findings are relevant to strategies for tumor immunotherapy in that they suggest that targeted cell surface expression of extracellular B7 determinants on tumor cells may be sufficient to induce effective anti-tumor responses, without the need for the transduction of full length B7 expression by tumor cells. The present results are consistent with the report by Brunschwig et al. that glycosylphosphotidyl-inositol-linked, non-transmembrane B7-1 and B7-2 retain their co-stimulatory function (32) . Although it was not addressed in the present study, it should be noted that the cytoplasmic tail of B7-1 and B7-2 may be required in signaling functions in cells such as APC or responding B cells. Studies designed to test this possibility are currently in progress.
In summary, the present studies have demonstrated that under the experimental conditions employed, both B7-1 and B7-2 are competent to provide co-stimulatory signals leading to rejection of B7-expressing tumor cells and the induction of EL4-specific immunity. The cytoplasmic domain of B7 is not required for co-stimulation in this experimental system. This host anti-tumor immune response is T cell dependent and requires the expression of CD28, presumably on host T cells. Taken together, these findings suggest a model in which CD28 on host T cells is engaged by B7 extracellular domains expressed by tumor cells, providing a co-stimulatory signal for the generation of an anti-tumor immune response.
